Nanobiotix S.A. American Depositary Shares

NANOBIOTIX completed a global offering raising approximately $100 million in gross proceeds through the full exercise of the underwriters' over-allotment option. The offering included 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. The company plans to allocate proceeds toward JNJ-1900 development (less than 10%),...

Nanobiotix, a late-clinical stage biotechnology company, announced the closing of its global offering on May 26, 2026, raising approximately $100 million in gross proceeds following the full exercise of underwriters' over-allotment option. The company issued 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. Net proc...

Nanobiotix, a late-clinical stage biotechnology company, announced the pricing of its global follow-on offering consisting of 225,373 ADSs in the U.S. at $38.98 per share and 1,959,289 ordinary shares plus 345,099 pre-funded warrants in Europe at €33.60 per share. The offering is expected to raise approximately €85.0 million in gross proceeds...

Nanobiotix announced a temporary trading halt on Euronext Paris effective May 21, 2026, to facilitate the pricing and allocation confirmation of its global follow-on offering. The offering consists of a U.S. public offering of American Depositary Shares and an international offering of ordinary shares and pre-funded warrants to qualified investor...

Nanobiotix, a late-clinical stage biotechnology company, announced the launch of an approximately €75 million (~$87 million) global follow-on offering consisting of American Depositary Shares and Ordinary Shares in the U.S. and Europe. The company plans to allocate proceeds toward advancing its Nanoprimer platform (50-60%), general corporate pu...